Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bachem Holding AGBCHMF 96 3-Year EPS without NRI Growth Rate is 9.00% as of Jun. 2026, which is 13% below its 10-year median of 10.30. GuruFocus rates BCHMF with a GF Score™ of 96/100 and a GF Value™ of $98.27 (Fairly Valued). The stock has 11 warning signs investors should review. Among 1,160 Biotechnology companies, Bachem Holding AG ranks worse than 58.97% on this metric.
During the past 12 months, Bachem Holding AG's average EPS without NRI Growth Rate was 6.30% per year.
During the past 3 years, the average EPS without NRI Growth Rate was 9.00% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 8.90% per year.
During the past 10 years, the average EPS without NRI Growth Rate was 15.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Bachem Holding AG was 41.50% per year. The lowest was -45.70% per year. And the median was 10.30% per year.
Bachem Holding AG (OTCPK:BCHMF) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Bachem Holding AG 3-Year EPS without NRI Growth Rate Related Terms
BCHMF vs VRTX, REGN, MRNA: 3-Year EPS without NRI Growth Rate Comparison
For the Biotechnology subindustry, Bachem Holding AG's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bachem Holding AG 3-Year EPS without NRI Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bachem Holding AG's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Bachem Holding AG's 3-Year EPS without NRI Growth Rate falls into.
Bachem Holding AG 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 9.00% mean?
Bachem Holding AG (BCHMF) has a 3-Year EPS without NRI Growth Rate of 9.00% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Bachem Holding AG and its competitors. This is 13% below median its historical median of 10.30. According to the industry distribution chart, Bachem Holding AG ranks #684 out of 1160 companies in the Biotechnology industry, placing it in the top 59%.
Is Bachem Holding AG's 3-Year EPS without NRI Growth Rate too high?
Bachem Holding AG's current 3-Year EPS without NRI Growth Rate of 9.00% is 13% below median its 10-year median of 10.30. The Biotechnology industry median 3-Year EPS without NRI Growth Rate is 16.05. Bachem Holding AG's value of 9.00% is 43.9% below this industry median. Based on the distribution chart, Bachem Holding AG ranks #684 out of 1160 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Bachem Holding AG has a GF Score™ of 96/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bachem Holding AG's 3-Year EPS without NRI Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Bachem Holding AG ranks #684 out of 1160 companies for 3-Year EPS without NRI Growth Rate. This places Bachem Holding AG in the lower half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 16.05. Bachem Holding AG's value of 9.00% is 43.9% below this benchmark. While the company's 10-year median is 10.30 vs. the industry median of 16.05, Bachem Holding AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Biotechnology company?
The median 3-Year EPS without NRI Growth Rate among Biotechnology companies is 16.05, based on 1,160 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bachem Holding AG's current 3-Year EPS without NRI Growth Rate of 9.00% is 43.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Bachem Holding AG and its competitors. For the Biotechnology industry, the median 3-Year EPS without NRI Growth Rate is 16.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bachem Holding AG's current 3-Year EPS without NRI Growth Rate is 9.00%, which is 13% below median its own 10-year median of 10.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bachem Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Bachem Holding AG (BCHMF) is currently considered Fairly Valued. The stock's GF Value™ is $98.27, compared to a current price of $91.00 — trading 7.4% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 9.00%, which is 13% below median its 10-year median of 10.30 and 43.9% below the Biotechnology industry median of 16.05. Bachem Holding AG's overall GF Score™ is 96/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Bachem Holding AG (BCHMF), the current 3-Year EPS without NRI Growth Rate is 9.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bachem Holding AG (BCHMF) Overvalued in 2026?
Based on GuruFocus' analysis, Bachem Holding AG stock appears to be undervalued.
The current stock price of $91.00 is trading 7.4% below its estimated GF Value™ of $98.27.
GuruFocus considers Bachem Holding AG to be Fairly Valued.
Key valuation signals for BCHMF:
3-Year EPS without NRI Growth Rate: 9.00% (13% below median its 10-year median of 10.30)
GF Value™: $98.27 vs. price of $91.00 (7.4% below fair value)
Industry Position: 43.9% below the Biotechnology median (#684 of 1160)
No single metric tells the full story. See the BCHMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bachem Holding AG is a biochemical company that provides services to the pharmaceutical and biotechnology industry. It focuses on specializing in the development and manufacture of peptides and oligonucleotides. The group markets its products under the Bachem and Clinalfa brands. Its products and services are CMC Development, Commercial API, Research and Specialities, and Services and Capabilities. Geographically, it operates in Switzerland, USA, Ireland, Denmark, United Kingdom, and Rest of the World.
96GF Score
Get the complete analysis for BCHMF
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BCHMF has been successfully added to your 
